AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zentalis Pharmaceuticals will participate in the Guggenheim Healthcare Innovation Conference and Stifel 2025 Healthcare Conference. Members of the management team will give a fireside discussion and company presentation, respectively. Access to live webcasts and archived recordings will be available on the company's website. Zentalis is developing azenosertib, a WEE1 inhibitor for ovarian cancer and other tumor types.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet